Select a medication above to begin.
Zepbound
tirzepatide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in patients with medullary thyroid carcinoma (MTC) history or family history, or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise patients of potential MTC risk and thyroid tumor symptoms (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: INJ (auto-injector): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg; INJ (KwikPen pen): 2.5 mg per injection, 5 mg per injection, 7.5 mg per injection, 10 mg per injection, 12.5 mg per injection, 15 mg per injection; INJ (vial): 10 mg per 2.4 mL, 20 mg per 2.4 mL, 30 mg per 2.4 mL, 40 mg per 2.4 mL, 50 mg per 2.4 mL, 60 mg per 2.4 mL, 2.5 mg per 0.5 mL, 5 mg per 0.5 mL, 7.5 mg per 0.5 mL, 10 mg per 0.5 mL, 12.5 mg per 0.5 mL, 15 mg per 0.5 mL
weight management, chronic
- [5-15 mg SC qwk]
- Start: 2.5 mg SC qwk x4wk, then 5 mg SC qwk, then may incr. by 2.5 mg/wk no more frequently than q4wk; Max: 15 mg/wk; Info: for obese patients or overweight patients with wt-related comorbidity; recommended maintenance dose is 5 mg, 10 mg, or 15 mg SC qwk
obstructive sleep apnea, moderate-severe
- [10-15 mg SC qwk]
- Start: 2.5 mg SC qwk x4wk, then 5 mg SC qwk, then incr. by 2.5 mg/wk no more frequently than q4wk; Max: 15 mg/wk; Info: for obese patients; recommended maintenance dose is 10 mg or 15 mg SC qwk
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.